Skip to content
value.today

Radionetics Oncology, Inc.

🇺🇸 Menlo Park, California, USAPharmaceuticalsFounded 2021
Total raised
$54 M
1 round on record
Latest round
$54 M
Aug 2023
First round on record
Aug 2023
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Radionetics Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2023$54 MNo. 1$50 to $250 million

Radionetics Oncology, Inc.: Raise no. 1, Aug 2023

Investors in this round

6 investors had bought by the notice of Aug 15, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$54 M of $69 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ana Kusnetzow · Executive Officer
  • Brett Ewald · Executive Officer
  • Dan Estes · Executive Officer, Director
  • Istvan Molnar · Executive Officer
  • Umesh Gangadharmath · Executive Officer
  • Yunfei Zhu · Executive Officer
  • Andrew Schwab · Director
  • Scott Struthers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brett Ewald, Interim Chief Operating Officer. Newest notice filed Aug 15, 2023. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Radionetics Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Radionetics Oncology, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Radionetics Oncology, Inc.
NameRoleNamed in
Ana KusnetzowExecutive officerAug 2023
Brett EwaldExecutive officerAug 2023
Dan EstesExecutive officerAug 2023
Istvan MolnarExecutive officerAug 2023
Umesh GangadharmathExecutive officerAug 2023
Yunfei ZhuExecutive officerAug 2023
Andrew SchwabDirectorAug 2023
Dan EstesDirectorAug 2023
Scott StruthersDirectorAug 2023